Inozyme Pharma to Present at the 21st Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY) announced that its CEO Axel Bolte will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 8:45 AM ET. The event will provide insights into the company’s development of INZ-701, a novel therapy targeting rare genetic diseases caused by ENPP1 and ABCC6 deficiencies. A replay of the chat will be available for 30 days in the Investor & News section of Inozyme’s website.

BOSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the 21^st Annual Needham Virtual Healthcare Conference on Wednesday, April 13^th at 8:45 AM ET.

A replay of the fireside chat can be accessed from the Investor & News section of Inozyme’s website under events and will be available for up to 30 days following the event.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue, and skeleton. Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization. We are initially focused on developing a novel therapy, INZ-701, to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies.

INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com

Contacts
Investors:
Inozyme Pharma
Stefan Riley, Director of Investor Relations
stefan.riley@inozyme.com        

Media:
SmithSolve
Matt Pera
973-886-9150
matt.pera@smithsolve.com

FAQ

What is the date of Inozyme Pharma's participation in the Needham Healthcare Conference?

Inozyme Pharma will participate in the Needham Healthcare Conference on April 13, 2022.

Who is representing Inozyme Pharma at the Needham Conference?

CEO Axel Bolte will represent Inozyme Pharma at the conference.

What is INZ-701 and its significance for Inozyme Pharma?

INZ-701 is a novel therapy being developed by Inozyme Pharma for treating rare genetic diseases related to ENPP1 and ABCC6 deficiencies.

How can I access the replay of the fireside chat from the Needham Conference?

The replay of the fireside chat will be available in the Investor & News section of Inozyme's website for 30 days after the event.

What is the focus of Inozyme Pharma's research?

Inozyme Pharma focuses on developing therapeutics for diseases caused by abnormal mineralization affecting the vasculature, soft tissue, and skeleton.